Nevertheless, although our findings suggest a possible role for IGFBP-4 in the pathophysiology of gastric cancer, the lack of separate measurement of intact IGFBP-4 levels limits the ability to directly assess the relationship between PAPP-A-mediated proteolysis and IGF bioavailability. This evidence concerns the gene IGF1 and gastric cancer.